|
1
|
Vora N and Reckamp KL: Non-small cell lung
cancer in the elderly: Defining treatment options. Semin Oncol.
35:590–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wheatley-Price P, Ding K, Seymour L, Clark
GM and Shepherd FA: Erlotinib for advanced non-small-cell lung
cancer in the elderly: An analysis of the National Cancer Institute
of Canada clinical trials group study BR.21. J Clin Oncol.
26:2350–2357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weiss GJ, Langer C, Rosell R, Hanna N,
Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA Jr
and Kelly K: Elderly patients benefit from second-line cytotoxic
chemotherapy: A subset analysis of a randomized phase III trial of
pemetrexed compared with docetaxel in patients with previously
treated advanced non-small-cell lung cancer. J Clin Oncol.
24:4405–4411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Charlson M, Szatrowski TP, Peterson J and
Gold J: Validation of a combined comorbidity index. J Clin
Epidemiol. 47:1245–1251. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alexander M, Evans SM, Stirling RG, Wolfe
R, Officer A, MacManus M, Solomon B, Burbury K and Ball D: The
influence of comorbidity and the simplified comorbidity score on
overall survival in non-small cell lung cancer-a prospective cohort
study. J Thorac Oncol. 11:748–757. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ball D, Thursfield V, Irving L, Mitchell
P, Richardson G, Torn-Broers Y, Wright G and Giles G: Evaluation of
the simplified comorbidity score (Colinet) as a prognostic
indicator for patients with lung cancer: A cancer registry study.
Lung Cancer. 82:358–361. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Colinet B, Jacot W, Bertrand D, Lacombe S,
Bozonnat MC, Daurès JP and Pujol JL: oncoLR health network: A new
simplified comorbidity score as a prognostic factor in
non-small-cell lung cancer patients: Description and comparison
with the Charlson's index. Br J Cancer. 93:1098–1105. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lindeman NI, Cagle PT, Beasley MB, Chitale
DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS,
Squire J, et al: Molecular testing guideline for selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors:
Guideline from the college of American pathologists, international
association for the study of lung cancer and association for
molecular pathology. J Mol Diagn. 15:415–453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006,
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdfAugust
9–2006
|
|
11
|
Imai H, Takahashi T, Mori K, Ono A,
Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, et
al: Individual-level data on the relationships of progression-free
survival, post-progression survival, and tumor response with
overall survival in patients with advanced non-squamous non-small
cell lung cancer. Neoplasma. 61:233–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DeAngelis LM, Delattre JY and Posner JB:
Radiation-induced dementia in patients cured of brain metastases.
Neurology. 39:789–796. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo
M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa K, et al:
Neurocognitive function of patients with brain metastasis who
received either whole brain radiotherapy plus stereotactic
radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys.
68:1388–1395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tanriverdi O, Avci N, Oktay E, Kalemci S,
Pilanci KN, Cokmert S, Menekse S, Kocar M, Sen CA, Akman T, et al:
Pretreatment serum albumin level is an independent prognostic
factor in patients with stage IIIB non-small cell lung cancer: A
study of the turkish descriptive oncological researches group.
Asian Pac J Cancer Prev. 16:5971–5976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kobayashi N, Usui S, Yamaoka M, Suzuki H,
Kikuchi S, Goto Y, Sakai M and Sato Y: The influence of serum
sodium concentration on prognosis in resected non-small cell lung
cancer. Thorac Cardiovasc Surg. 62:338–343. 2014.PubMed/NCBI
|
|
16
|
Castillo JJ, Vincent M and Justice E:
Diagnosis and management of hyponatremia in cancer patients.
Oncologist. 17:756–765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simons JP, Schols AM, Buurman WA and
Wouters EF: Weight loss and low body cell mass in males with lung
cancer: Relationship with systemic inflammation, acute-phase
response, resting energy expenditure, and catabolic and anabolic
hormones. Clin Sci (Lond). 97:215–223. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang JS, Chen LT, Shan YS, Lin SF, Hsiao
SY, Tsai CR, Yu SJ and Tsai HJ: Comprehensive analysis of the
incidence and survival patterns of lung cancer by histologies,
including rare subtypes, in the era of molecular medicine and
targeted therapy: A nation-wide cancer registry-based study from
Taiwan. Medicine (Baltimore). 94:e9692015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Islam KM, Jiang X, Anggondowati T, Lin G
and Ganti AK: Comorbidity and survival in lung cancer patients.
Cancer Epidemiol Biomarkers Prev. 24:1079–1085. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jacot W, Colinet B, Bertrand D, Lacombe S,
Bozonnat MC, Daurès JP and Pujol JL; Onco LR health network, :
Quality of life and comorbidity score as prognostic determinants in
non-small-cell lung cancer patients. Ann Oncol. 19:1458–1464. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuo YW, Jerng JS, Shih JY, Chen KY, Yu CJ
and Yang PC: The prognostic value of the simplified comorbidity
score in the treatment of small cell lung carcinoma. J Thorac
Oncol. 6:378–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim ES, Hirsh V, Mok T, Socinski MA,
Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al:
Gefitinib versus docetaxel in previously treated non-small-cell
lung cancer (INTEREST): A randomised phase III trial. Lancet.
372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun JM, Lee KH, Kim SW, Lee DH, Min YJ,
Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, et al: Gefitinib versus
pemetrexed as second-line treatment in patients with nonsmall cell
lung cancer previously treated with platinum-based chemotherapy
(KCSG-LU08-01): An open-label, phase 3 trial. Cancer.
118:6234–6242. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garassino MC, Martelli O, Broggini M,
Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F,
Moscetti L, et al: Erlotinib versus docetaxel as second-line
treatment of patients with advanced non-small-cell lung cancer and
wild-type EGFR tumours (TAILOR): A randomised controlled trial.
Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawaguchi T, Ando M, Asami K, Okano Y,
Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, et al:
Randomized phase III trial of erlotinib versus docetaxel as second-
or third-line therapy in patients with advanced non-small-cell lung
cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin
Oncol. 32:1902–1908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao HY, Zhang Y, Huang H, Chen LK, Xu GC
and Zhang L: Efficacy of erlotinib on advanced non-small cell lung
cancer. Ai Zheng. 27:393–399. 2008.(In Chinese). PubMed/NCBI
|
|
27
|
Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang
BX and Wang SY: A randomized phase 2 trial of erlotinib versus
pemetrexed as second-line therapy in the treatment of patients with
advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Cancer. 120:1379–1386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma K, Cohen V, Kasymjanova G, Small D,
Novac K, Peterson J, Levit A and Agulnik J: An exploratory
comparative analysis of tyrosine kinase inhibitors or docetaxel in
second-line treatment of EGFR wild-type non-small-cell lung cancer:
A retrospective real-world practice review at a single tertiary
care centre. Curr Oncol. 22:e157–e163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B,
Kim TM, Lee SH and Heo DS: Epidermal growth factor receptor
tyrosine kinase inhibitors vs conventional chemotherapy in
non-small cell lung cancer harboring wild-type epidermal growth
factor receptor: A meta-analysis. JAMA. 311:1430–1437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao N, Zhang XC, Yan HH, Yang JJ and Wu
YL: Efficacy of epidermal growth factor receptor inhibitors versus
chemotherapy as second-line treatment in advanced non-small-cell
lung cancer with wild-type EGFR: A meta-analysis of randomized
controlled clinical trials. Lung Cancer. 85:66–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vale CL, Burdett S, Fisher DJ, Navani N,
Parmar MK, Copas AJ and Tierney JF: Should tyrosine kinase
inhibitors be considered for advanced non-small-cell lung cancer
patients with wild type EGFR? Two systematic reviews and
meta-analyses of randomized trials. Clin Lung Cancer.
16:173–182.e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gironés R, Torregrosa D, Gómez-Codina J,
Maestu I, Tenias JM and Rosell R: Prognostic impact of comorbidity
in elderly lung cancer patients: Use and comparison of two scores.
Lung Cancer. 72:108–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Haruki T, Yurugi Y, Wakahara M, Matsuoka
Y, Miwa K, Araki K, Taniguchi Y and Nakamura H: Simplified
comorbidity score for elderly patients undergoing thoracoscopic
surgery for lung cancer. Surg Today. 47:718–725. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meng X, Liu Y, Zhang J, Teng F, Xing L and
Yu J: PD-1/PD-L1 checkpoint blockades in non-small cell lung
cancer: New development and challenges. Cancer Lett. 405:29–37.
2017. View Article : Google Scholar : PubMed/NCBI
|
